OnDemand

As more states adopt drug pricing transparency laws to help lower the cost of prescription drugs, pharmaceutical manufacturers, especially those about to launch their first therapy, must understand the changing legal landscape and what it means for their business now and in the future.

In this informative discussion, Rupal Patel, Director of Advisory Services, and John Whitridge, Senior Advisory Services Consultant discuss the current state of drug pricing transparency laws, including:

• What manufacturers can do now to comply with existing laws
• How pre-commercial companies can gain a competitive advantage at launch
• Lessons learned from over 50 customer implementations

Rupal Patel    John Whitridge

Please fill out the form to listen to the discussion.

To download our datasheet detailing solutions to reduce compliance risk around state price transparency, click here.